Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Retained Earnings: 2013-2025

Historic Retained Earnings for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $642.5 million.

  • Amphastar Pharmaceuticals' Retained Earnings rose 21.03% to $642.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $642.5 million, marking a year-over-year increase of 21.03%. This contributed to the annual value of $568.8 million for FY2024, which is 38.98% up from last year.
  • Amphastar Pharmaceuticals' Retained Earnings amounted to $642.5 million in Q3 2025, which was up 2.78% from $625.1 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Retained Earnings peaked at $642.5 million during Q3 2025, and registered a low of $122.8 million during Q1 2021.
  • Its 3-year average for Retained Earnings is $482.6 million, with a median of $490.4 million in 2024.
  • Data for Amphastar Pharmaceuticals' Retained Earnings shows a peak YoY skyrocketed of 69.96% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Retained Earnings stood at $180.3 million in 2021, then skyrocketed by 50.68% to $271.7 million in 2022, then skyrocketed by 50.62% to $409.3 million in 2023, then surged by 38.98% to $568.8 million in 2024, then rose by 21.03% to $642.5 million in 2025.
  • Its Retained Earnings stands at $642.5 million for Q3 2025, versus $625.1 million for Q2 2025 and $594.1 million for Q1 2025.